AXIM Biotechnologies, Inc. (AXIM)

OTCMKTS · Delayed Price · Currency is USD
0.0111
0.00 (0.00%)
At close: Feb 27, 2026
236.36%
Market Cap 4.03M
Revenue (ttm) 92.90K
Net Income (ttm) -4.14M
Shares Out 363.13M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,703
Average Volume 101,135
Open 0.0099
Previous Close 0.0111
Day's Range 0.0099 - 0.0114
52-Week Range 0.0029 - 0.0288
Beta -0.64
RSI 43.37
Earnings Date n/a

About AXIM Biotechnologies

AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol AXIM
Full Company Profile

Financial Performance

In 2023, AXIM Biotechnologies's revenue was $39,518, an increase of 345.27% compared to the previous year's $8,875. Losses were -$8.06 million, 29.1% more than in 2022.

Financial Statements

News

There is no news available yet.